AHRQ poses questions on sleep apnea
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research and Quality circulates six questions Oct. 7 on the comparative effectiveness of diagnosis and treatment of obstructive sleep apnea. AHRQ seeks public comments on: how the various available tests compare for diagnosing sleep apnea in adults with symptoms suggestive of disordered sleep; how phased testing compares with full testing alone; what the effect of pre-operative screening for sleep apnea is on surgical outcomes; the comparative effects of various sleep apnea treatments; the pre-treatment patient-level characteristics associated with failure to treat obstructive sleep apnea; and the effect of interventions to improve compliance with sleep apnea treatment devices on clinical outcomes
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.